Efficacy and safety of edaravone sublingual tablet for patients with cerebral small vessel disease-related cognitive impairment: study protocol for a multicentre, randomised, double-blind, placebo-controlled trial
{{output}}
Background: Cerebral small vessel disease (CSVD) represents a leading aetiology of vascular cognitive impairment, yet effective treatments for CSVD-related cognitive impairment (CSVD-CI) are limited. Although edaravone has shown ... ...
